204 related articles for article (PubMed ID: 26679963)
1. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
Smith MY; Sabidó-Espin M; Trochanov A; Samuelson M; Guedes S; Corvino FA; Richy FF
J Manag Care Spec Pharm; 2015 Aug; 21(8):650-60. PubMed ID: 26233537
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
6. Serious Adverse Events Reported with Dietary Supplement Use in the United States: A 2.5 Year Experience.
Schmitz SM; Lopez HL; Mackay D; Nguyen H; Miller PE
J Diet Suppl; 2020; 17(2):227-248. PubMed ID: 30513022
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
8. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
10. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
11. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
12. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
Knisely BM; Hatim Q; Vaughn-Cooke M
Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
14. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
15. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
16. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
17. Is pharmacovigilance of biologicals cost-effective?
Claus B
Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
[TBL] [Abstract][Full Text] [Related]
19. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
[TBL] [Abstract][Full Text] [Related]
20. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
